US Coverage

Law360 Authority | Deep News & Analysis

Global Coverage

Law360 Pulse | The Business of Law

Mealeys

MLex

Gene Therapy Developer Sangamo Hits Ch. 11 With Sale Plans

By Clara Geoghegan · June 23, 2026, 11:46 AM EDT

Sangamo Therapeutics Inc. filed for bankruptcy protection in Delaware on Tuesday with offers to sell parts of its genetic therapy development programs to Eli Lilly and Co. and Astellas Pharma Inc....

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Bankruptcy Scorecard

Summary

Sangamo Therapeutics Inc. filed for bankruptcy protection in Delaware on Tuesday with offers to sell parts of its genetic therapy development programs to Eli Lilly and Co. and Astellas Pharma Inc.

Case Number

1:26-bk-10989

Judge

Craig Goldblatt

Venue

U.S. Bankruptcy Court for the District of Delaware

Capital Structure

Total Liabilities:

$100 million to $500 million

View Full Scorecard

Documents

Related Sections

Case Information

Case Title

Sangamo Therapeutics, Inc.

Case Number

1:26-bk-10989

Court

Delaware

Nature of Suit

Date Filed

June 23, 2026

Recent Articles By Clara